Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis

Interferon‐α2 reduces elevated blood cell counts and splenomegaly in patients with myeloproliferative neoplasms (MPN) and may restore polyclonal hematopoiesis. Its use is limited by inflammation‐mediated toxicity, leading to treatment discontinuation in 10‐30% of patients. Ruxolitinib, a potent anti...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Med
Auteurs principaux: Mikkelsen, Stine Ulrik, Kjær, Lasse, Bjørn, Mads Emil, Knudsen, Trine Alma, Sørensen, Anders Lindholm, Andersen, Christen Bertel Lykkegaard, Bjerrum, Ole Weis, Brochmann, Nana, Fassi, Daniel El, Kruse, Torben A., Larsen, Thomas Stauffer, Mourits‐Andersen, Hans Torben, Nielsen, Claus Henrik, Pallisgaard, Niels, Thomassen, Mads, Skov, Vibe, Hasselbalch, Hans Carl
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2018
Sujets:
Clinical Cancer Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089176/
https://ncbi.nlm.nih.gov/pubmed/29932310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1619
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires